LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option TOKYO and CAMBRIDGE, Mass., Jan. 13, 2025 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and…

SAN DIEGO, Jan. 13, 2025 /PRNewswire/ — Johnson Fistel, LLP announces that its Denver, Colorado office has filed a class action lawsuit on behalf of all purchasers of DMC Global Inc. (NASDAQ: BOOM) securities during the period between May 3, 2024 and November 4, 2024, both dates…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.